ストックスクリーナーアプリを入手
401.80
2.44%
9.56
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
What are the technical indicators suggesting about Alnylam Pharmaceuticals Inc.Discover the fastest growing stocks today - jammulinksnews.com
What catalysts could drive Alnylam Pharmaceuticals Inc. stock higher in 2025Exceptional risk-adjusted gains - jammulinksnews.com
Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastMaximize gains with strategic stock entries - jammulinksnews.com
Alnylam Pharmaceuticals' Q2 2025: Unraveling Key Contradictions in AMVUTTRA's Market Strategy and Patient Access - AInvest
Is it the right time to buy Alnylam Pharmaceuticals Inc. stockBreakout Stocks Signals Backed By Experts - jammulinksnews.com
BMO Capital Reaffirms Buy Rating on Alnylam Pharma with $450 Price Target - AInvest
Alnylam Pharmaceuticals Sees Strong Sales of Rare Disease Drug, Raises Revenue Guidance - AInvest
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance - AOL.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
Alnylam projects $2.65B–$2.8B 2025 revenue following AMVUTTRA ATTR-CM launch momentum - MSN
Why Is Alnylam Stock Gaining Friday?Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga
How volatile is Alnylam Pharmaceuticals Inc. stock compared to the marketTop Growth Insights With High Returns - jammulinksnews.com
Alnylam soars past $50B market cap - The Business Journals
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up - TradingView
Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - simplywall.st
Alnylam Pharmaceuticals, Inc to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates - MSN
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2025 Earnings Call Transcript - Insider Monkey
Narrow-Moat Alnylam's Strong Launch of Amvuttra for ATTR-CM Drives Growth; Pipeline Makes Progress - Morningstar
Alnylam Pharmaceuticals Lifts Revenue Outlook After Earnings Beat - Finimize
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress - BioSpace
Alnylam Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Widens 292% - AInvest
Alnylam Pharmaceuticals Inc (ALNY) Q2 2025 Earnings Call Highlig - GuruFocus
Alnylam Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus
Alnylam: Q2 Earnings Snapshot - Norwalk Hour
Alnylam Soars 15.43% on $1.31B Trade Volume Surge as TTR Revenues Jump 64% and Raised 2025 Outlook - AInvest
Amvuttra's stellar performance pushes Alnylam's guidance, stock higher - FirstWord Pharma
Alnylam Pharmaceuticals Surges 15.43% On Strong Technical Breakout - AInvest
Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches - insights.citeline.com
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast - inkl
Alnylam's Amvuttra: A Game-Changer in ATTR-CM and a Catalyst for Biotech Growth - AInvest
Alnylam: Amvuttra Is Just Getting Started (NASDAQ:ALNY) - Seeking Alpha
Alnylam reaches new highs on strong sales of closely watched rare disease drug - BioPharma Dive
Earnings call transcript: Alnylam’s Q2 2025 results boost stock by 18% - Investing.com Nigeria
Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates - Investing.com
Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals Surpasses Wall Street Expectations in Q2News and Statistics - IndexBox
Alnylam jumps on full year revenue guidance raise (ALNY) - Seeking Alpha
Alnylam Q2 2025 slides: ATTR-CM launch drives 64% revenue growth, guidance raised - Investing.com Canada
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alnylam Pharmaceuticals Skyrockets 12.3%—What’s Fueling This Biotech Surge? - AInvest
Alnylam Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Why is Alnylam Pharmaceuticals Inc. stock attracting strong analyst attentionStock Market Guidance With High Returns - jammulinksnews.com
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results - TradingView
ALNYLAM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Alnylam Q2 2025 rev. $672 mln, up 64% YoY, raises TTR guidance to $2.175 bln-$2.275 bln. - AInvest
Amvuttra's first full-quarter sales for ATTR-CM are in. And they're a boon for Alnylam - Endpoints News
RNAi biotech founded by former Alnylam CEO expands Cambridge footprint - The Business Journals
Alnylam Outpaces The Market With RNAi Growth Story - Finimize
From inception to launch: City Therapeutics finds space in the heart of innovation - JLL
Alnylam Pharmaceuticals stock hits all-time high at 335.0 USD By Investing.com - Investing.com South Africa
Bernstein raises Alnylam Pharmaceuticals stock price target on Amvuttra outlook - Investing.com Canada
2.46%
0.70%
大文字化:
|
ボリューム (24 時間):